Patient P-03357
Therapy response
Declining
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Unstable
Nutritional resilience
Improving
Discontinuation risk
49%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S02
- Day 101 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 102 CR-01 recommended — Clinician Review CR-01
- Day 103 Patient accepted — Started CR-01 in the companion
- Day 108 Deterioration detected before clinical escalation — Clinician Review CR-01
What changed?
Trajectory began diverging from predicted response on Day 101.
Primary contributors, last 14 days
- Nutritional resilience+8
- Toxicity+6
- GI instability-5
- Inflammatory activity+5
- Treatment adherence-4
What helped?
- Clinician Review CR-01Day 102Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
52%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 81% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 26/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 52 and rising
- WearableSleep 5.4 h, below personal baseline
- Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 59
- Drug metabolism and exposure ↑20
- BloodToxicity index 47
- Autonomic recovery ↑20
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3.1 · butyrate capacity 26/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 55 ms
- Sleep
- 5.4 h
- Steps
- 5,379
- Resting HR
- 67 bpm
Daily log: GI score 52, nutritional resilience 44, adherence 70.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03046 | 48% | S20 | GI-04 | no change | 53 |
| P-03260 | 48% | S19 | — | — | 54 |
| P-03271 | 43% | S19 | — | — | 66 |
| P-03352 | 43% | S19 | — | — | 59 |
| P-03465 | 42% | S17 | CR-01 | improved | 65 |
| P-03164 | 41% | S11 | — | — | 58 |
| P-03267 | 41% | S05 | — | — | 62 |
| P-03004 | 38% | S03 | — | — | 56 |
| P-03191 | 38% | S19 | GI-04 | improved | 51 |
| P-03444 | 38% | S17 | — | — | 62 |
| P-03080 | 37% | S09 | — | — | 62 |
| P-03123 | 37% | S14 | GI-04 | improved | 50 |